
Ask a doctor about a prescription for OLMESARTAN/HYDROCHLOROTHIAZIDE TEVA 40 mg/12.5 mg FILM-COATED TABLETS
Package Leaflet:information for the user
Olmesartan/Hydrochlorothiazide Teva 40 mg/12.5 mg film-coated tablets EFG
Olmesartan medoxomil/hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine,because it contains important information for you.
Contents of the pack
This medicine contains two active substances, olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension):
This medicine is given to you only if treatment with olmesartan medoxomil alone has not controlled your blood pressure sufficiently. The combination of the two active substances in this medicine helps to lower blood pressure more than either substance alone.
You may already be taking medicines to treat high blood pressure, but your doctor may think it is necessary for you to take this medicine to lower it further.
High blood pressure can be controlled with medicines such as this. Your doctor has probably also advised you to make some changes to your lifestyle to help lower your blood pressure (e.g. lose weight, stop smoking, reduce alcohol consumption and reduce the amount of salt in your diet). Your doctor may have also advised you to take regular exercise, such as walking or swimming. It is important to follow your doctor's advice.
Do not take Olmesartan/Hydrochlorothiazide Teva:
If you think any of these apply to you, or if you are unsure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Talk to your doctor before you start taking this medicine.
Before taking the tablets tell your doctorif you are taking any of the following medicines used to treat high blood pressure (hypertension):
Your doctor may want to check your kidney function, blood pressure and levels of electrolytes (e.g. potassium) in your blood at regular intervals.
See also the information under the heading “Do not take Olmesartan/Hydrochlorothiazide Teva”.
Before taking the tablets, tell your doctorif you have any of the following health problems:
Tell your doctor if you experience any of the following symptoms:
Your doctor may want to see you more often and perform some tests if you have any of these problems.
Talk to your doctor if you experience abdominal pain, nausea, vomiting or diarrhoea after taking this medicine. Your doctor will decide on the treatment to follow. Do not stop taking this medicine on your own.
This medicine may cause an increase in blood fat and uric acid levels (which can cause gout - painful swelling of the joints). Your doctor will probably want to perform a blood test from time to time to monitor these possible changes.
A change in blood levels of certain chemicals called electrolytes may occur. Your doctor will probably want to perform a blood test from time to time to monitor this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, tiredness, drowsiness or restlessness, nausea, vomiting, decreased need to urinate, rapid heartbeat. Tell your doctor if you notice any of these symptoms.
As with any other medicine that lowers blood pressure, an excessive drop in blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will carefully monitor your blood pressure.
If you are going to have parathyroid function tests, you must stop taking this medicine before these tests are performed.
You must inform your doctor if you are pregnant or think you might be pregnant. This medicine is not recommended during pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken after this time (see section Pregnancy).
Children and adolescents
This medicine is not recommended for children and adolescents under 18 years of age.
Other medicines and Olmesartan/Hydrochlorothiazide Teva
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines:
Taking Olmesartan/Hydrochlorothiazide Teva with food, drinks and alcohol
Olmesartan/Hydrochlorothiazide Teva can be taken with or without food.
Be careful when drinking alcohol while taking this medicine, as some people feel weak or dizzy. If this happens to you, do not drink any alcohol, including wine, beer or alcohol-containing refreshments.
Black patients
As with other similar medicines, the blood pressure-lowering effect of olmesartan/hydrochlorothiazide is somewhat smaller in black patients.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Pregnancy
You must tell your doctor if you are pregnant (or think you might be). Your doctor will normally advise you to stop taking this medicine before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Olmesartan/Hydrochlorothiazide Teva. This medicine is not recommended during pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken after this time.
Breast-feeding
Tell your doctor if you are breast-feeding or will start breast-feeding. This medicine is not recommended during breast-feeding, and your doctor will choose another treatment for you if you want to breast-feed.
Driving and using machines
You may feel drowsy or dizzy while taking this medicine for high blood pressure. If this happens, do not drive or use machines until the symptoms have gone away. Talk to your doctor.
Use in athletes
Athletes are informed that this medicine contains a component (hydrochlorothiazide) that may result in a positive doping test.
Olmesartan/Hydrochlorothiazide Teva contains lactose and orange yellow S
Lactose: If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Orange yellow S: May cause allergic reactions.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended doseis one Olmesartan/Hydrochlorothiazide Teva 40 mg/12.5 mg tablet per day. If your blood pressure is not controlled sufficiently, your doctor may change your dose to one Olmesartan/Hydrochlorothiazide Teva 40 mg/25 mg tablet per day.
Swallow the tablet with water. Do not chew, crush or break it. If possible, take your dose at the same time each day, e.g. at breakfast time. It is important that you continue to take this medicine until your doctor tells you to stop.
If you take more Olmesartan/Hydrochlorothiazide Teva than you should
If you take more tablets than you should, or if a child accidentally takes some, contact your doctor or go to the nearest hospital emergency department immediately and take the medicine pack with you.
In case of overdose or accidental ingestion, consult your doctor, pharmacist or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Olmesartan/Hydrochlorothiazide Teva
If you forget to take a dose, take your normal dose the next day. Do nottake a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Hydrochlorothiazide Teva
It is important to continue taking this medicine, unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
However, the following adverse effects can be serious:
This medicine is a combination of two active ingredients. The following information, first, describes the adverse effects reported so far with the combination of olmesartan medoxomil and hydrochlorothiazide (in addition to those already mentioned) and, second, the known adverse effects of the two active ingredients separately.
These are other known adverse effects so far with olmesartan/hydrochlorothiazide:
If these adverse effects occur, they are often mild and it is not necessary to interrupt treatment.
Common adverse effects (may affect up to 1 in 10 people):
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Uncommon adverse effects (may affect up to 1 in 100 people):
Somnolence, rapid and intense heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, back pain, erection problems in men, blood in urine.
Some changes in blood tests have also been observed infrequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased liver function test values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Rare adverse effects (may affect up to 1 in 1,000 people):
Feeling of discomfort, altered consciousness, skin lumps (hives), acute kidney failure.
Some changes in blood test results have also been observed rarely, including:
Increased blood urea nitrogen, decreased hemoglobin and hematocrit values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Additional adverse effects reported with the use of olmesartan medoxomil or hydrochlorothiazide alone, but not with the combination of olmesartan/hydrochlorothiazide or at a higher frequency:
Olmesartan medoxomil:
Common adverse effects (may affect up to 1 in 10 people):
Bronchitis, cough, nasal congestion or secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Some changes in blood test results have also been observed frequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased liver or muscle function test values.
Uncommon adverse effects (may affect up to 1 in 100 people):
Rapid allergic reactions that can affect the whole body and cause breathing problems, as well as a rapid drop in blood pressure that can lead to fainting (anaphylactic reactions), facial inflammation, angina (chest pain or discomfort, known as angina pectoris), feeling of discomfort, allergic skin rash, itching, exanthema (skin rash), skin lumps (hives).
Some changes in blood test results have also been observed infrequently, including:
Reduction in the number of a type of blood cell called platelets (thrombocytopenia).
Rare adverse effects (may affect up to 1 in 1,000 people):
Worsening of kidney function, lack of energy.
Intestinal angioedema: intestinal inflammation that manifests with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Some changes in blood test results have also been observed rarely, including:
Increased potassium levels in the blood.
Hydrochlorothiazide:
Very common adverse effects (may affect more than 1 in 10 people):
Changes in blood tests, including: increased fat and uric acid levels in the blood.
Common adverse effects (may affect up to 1 in 10 people):
Feeling of confusion, abdominal pain, stomach discomfort, feeling of bloating, diarrhea, nausea, vomiting, constipation, glucose excretion in urine.
Some changes in blood test results have also been observed, including:
Increased creatinine, urea, calcium, and blood sugar levels, decreased chloride, potassium, magnesium, and sodium levels in the blood. Increased serum amylase (hyperamylasemia).
Uncommon adverse effects (may affect up to 1 in 100 people):
Decreased or loss of appetite, severe breathing difficulties, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions due to light sensitivity, itching, purple spots or patches on the skin due to small hemorrhages (purpura), skin lumps (hives).
Rare adverse effects (may affect up to 1 in 1,000 people):
Inflammation and pain of the salivary glands, decreased number of white blood cells, decreased number of platelets in the blood, anemia, bone marrow damage, restlessness, feeling "depressed" or depressed, sleep problems, loss of interest (apathy), tingling and numbness, seizures (convulsions), yellowish perception of objects when looking at them, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in the lungs, pancreatitis, jaundice, infection in the gallbladder, symptoms of lupus erythematosus (such as skin rash, joint pain, and cold hands and feet), allergic skin reactions, skin peeling and blisters, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness (which can sometimes cause movement disorders).
Very rare adverse effects (may affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause an abnormally low level of chloride in the blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus).
Acute respiratory distress (signs include severe respiratory distress, fever, weakness, and confusion).
Unknown adverse effects (frequency cannot be estimated from available data):
Skin and lip cancer (non-melanoma skin cancer).
Decreased vision or eye pain due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiration date that appears on the box or blister after CAD. The expiration date is the last day of the month indicated.
Medicines should not be thrown away through wastewater or household waste. Deposit the packaging and medicines you no longer need in the SIGRE
point at the pharmacy. In case of doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Composition of Olmesartan/Hydrochlorothiazide Teva
Core of the tablet:Lactose monohydrate, low-substituted hydroxypropylcellulose, hydroxypropylcellulose, microcrystalline cellulose Type 102, magnesium stearate
Coating of the tablet:Opadry II Orange 33G23991 which contains: hypromellose 6cP, titanium dioxide (E171), lactose monohydrate, macrogol 3350, triacetin (E1518), yellow iron oxide (E172), red iron oxide (E172), orange yellow S (E110)
Appearance of the Product and Package Contents
Olmesartan/Hydrochlorothiazide Teva 40 mg/12.5 mg are film-coated orange, oval, biconvex tablets, 15 x 7 mm in size, with OH 41 engraved on one side.
Package Sizes
Blister packs (Al-Al): 14, 28, 30, 56, 98 film-coated tablets.
Calendar blister packs (Al-Al): 28 film-coated tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Teva B.V.
Swensweg 5,
2031GA Haarlem
Netherlands
Manufacturer
Actavis Ltd.
BLB016, Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Teva Pharma S.L.U.
C/ Anabel Segura, 11, Edificio Albatros B, 1ª planta
28108 Alcobendas, Madrid (Spain)
Date of the last revision of this prospectus:December 2021
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)
You can access detailed and updated information about this medicine by scanning the QR code included in the packaging with your mobile phone (smartphone). You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/86788/P_86788.html
QR Code + URL
The average price of OLMESARTAN/HYDROCHLOROTHIAZIDE TEVA 40 mg/12.5 mg FILM-COATED TABLETS in December, 2025 is around 20.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/HYDROCHLOROTHIAZIDE TEVA 40 mg/12.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.